Targeting Oncogenic BRAF in Human Cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
MAPK pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. BRAF missense kinase domain mutations, the vast majority of which are V600E, occur in approximately 8% of human tumors. These mutations, which are non-overlapping in distribution with RAS mutations, are observed most frequently in melanoma but also in tumors arising in the colon, thyroid, lung and other sites. Supporting its classification as an oncogene, V600EBRAF stimulates ERK signaling, induces proliferation and is capable of promoting transformation. Given the frequent occurrence of BRAF mutations in human cancer and the continued requirement for BRAF activity in the tumors in which it is mutated, efforts are underway to develop targeted inhibitors of BRAF and its downstream effectors. These agents offer the possibility of greater efficacy and less toxicity than the systemic therapies currently available for tumors driven by activating mutations in the MAPK pathway. Early clinical results with the BRAF-selective inhibitors PLX4032 and GSK2118436 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by oncogenic BRAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“Furthermore, transfection of mutant BRAF into non-transformed human melanocytes has been shown to induce p16 expression, cell cycle arrest and senescence (Michaloglou et al. 2005).”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×
“Over 25 years have passed since oncogenic RAS was first identified as the transforming factor in the Harvey and Kirsten strains of the Mouse Sarcoma Virus (Chang et al. 1982; Der et al. 1982; Malumbres and Barbacid 2003; Shimizu et al. 1983).”
BackgroundHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 1×
“Activating BRAF mutations are, however, present in the majority of melanocytic nevi, benign skin lesions that rarely progress to melanoma (Pollock et al. 2003).”
BackgroundGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 1×
“Several candidate cooperative genetic alterations have been identified in melanoma, including MITF amplification and mutation and/or deletion of the tumor suppressor genes PTEN, TP53 and CDKN2A (Dankort et al. 2009; Dankort et al. 2007; Garraway et al. 2005).”
BackgroundCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · cited 1×
“Pathway activity is also regulated by cross-talk with parallel signaling pathways, such as by AKT phosphorylation of inhibitory sites on RAF (Zimmermann and Moelling 1999) and through PI3K-dependent feedback (Carracedo et al. 2008).”
BackgroundBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903 · cited 1×
“In melanocytes, loss of IGFBP7 may also allow for escape from BRAF mediated senescence (Wajapeyee et al. 2008).”
BackgroundSprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · cited 1×
“The inducible expression of SPRY family members by ERK activation follows the classic pattern of a negative feedback loop whereby the expression of negative feedback regulator is controlled by the signaling pathways that it ultimately regulates (Hanafusa et al. 2002).”
BackgroundKSR modulates signal propagation within the MAPK cascade.
Therrien, M., Michaud, N. R., Rubin, G. M., & Morrison, D. K. (1996) · Genes & Development · doi:10.1101/gad.10.21.2684 · Cited by 257
Cited by
Rodriguez-Galindo, C., & Allen, C. E. (2020) · Blood · doi:10.1182/blood.2019000934 · Cited by 361
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P. (2021) · G3 Genes|Genomes|Genetics · doi:10.1093/g3journal/jkaa069 · Cited by 20
“BRAF, the target of vemurafenib, is the RAF component of the MAPK signaling pathway that is frequently hyperactivated in cancer cells (Pratilas et al. 2012), MAPK pathway consists of 1G protein RAS, and 3 kinases RAF, MEK, and ERK.”
BackgroundExpert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14
Metadata
- Authors
- Pratilas, C. A., Xing, F., & Solit, D. B.
- Venue
- Current Topics in Microbiology and Immunology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2010
- Volume
- 355
- Pages
- 83-98
- ISSN
- 0070-217X (ISSN-L)
- OpenAlex
- W1543819161
- Cited by
- 61
- References
- 11
- FWCI
- 3.49
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Oncogenic BRAF in Human Cancer. https://app.cochat.ai/papers/10.1007/82_2011_162
- The paper
- Pratilas, C. A., Xing, F., & Solit, D. B. (2010). Targeting Oncogenic BRAF in Human Cancer. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/82_2011_162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.